Fluoroquinolone Resistance in Penicillin-resistant Streptococcus pneumoniae Clones, Spain by de la Campa, Adela G. et al.
Among 2,882 Streptococcus pneumoniae sent to the
Spanish Reference Laboratory during 2002, 75 (2.6%)
were ciprofloxacin-resistant. Resistance was associated
with older patients (3.9% in adults and 7.2% in patients ≥65
years of age), with isolation from noninvasive sites (4.3%
vs. 1.0%), and with penicillin and macrolide resistance.
Among 14 low-level resistant (MIC 4–8 µg/mL) strains, 1
had a fluoroquinolone efflux phenotype, and 13 showed
single ParC changes. The 61 high-level ciprofloxacin-
resistant (MIC ≥16  µg/mL) strains showed either two or
three changes at ParC, ParE, and GyrA. Resistance was
acquired either by point mutation (70 strains) or by recom-
bination with viridans streptococci (4 strains) at the topoi-
somerase II genes. Although 36 pulsed-field gel
electrophoresis patterns were observed, 5 international
multiresistant clones (Spain23F-1, Spain6B-2, Spain9V-3,
Spain14-5 and Sweden15A-25) accounted for 35 (46.7%) of
the ciprofloxacin-resistant strains. Continuous surveillance
is needed to prevent the dissemination of these clones. 
R
esistance of Streptococcus pneumoniae to multiple
antibacterial agents, including β-lactams, macrolides,
tetracyclines, and co-trimoxazole, has emerged worldwide
in the 1980s and 1990s (1–3) and has emphasized the need
for new therapeutic alternatives, such as newer fluoro-
quinolones. Older fluoroquinolones, such as ciprofloxacin
and ofloxacin, have been widely used in the last 2 decades,
but their activity against gram-positive pathogens is limit-
ed. Newer fluoroquinolones, such as levofloxacin, gati-
floxacin, moxifloxacin, and gemifloxacin, have enhanced
activity against most respiratory pathogens, and some are
being more widely used to treat respiratory tract infections.
Therefore, the emergence of fluoroquinolone-resistant S.
pneumoniae strains, although worldwide prevalence is
low, is a concern to clinicians who manage respiratory
tract infections. A global surveillance study from 1998 to
2000 included 8,882 pneumococci isolated from blood and
sputum samples that were collected from centers in 26
countries. The study showed a 1.1% prevalence of
ofloxacin-resistant strains, although in some places higher
values of nonsusceptible ofloxacin strains were observed:
10.1% in Israel, 14.1% in Japan, and 22.3% in Hong Kong
(1). Ciprofloxacin-resistant strains isolated from patients
with community-acquired respiratory tract infections have
been reported in Spain (3.0% [4] and 7.1% [5]), Canada
(1.7% [6]), and the United States (1.4% [7]).
Fluoroquinolone resistance is higher among related
viridans group streptococci (VGS) isolated from blood (8).
Increased fluoroquinolone use correlates with an increase
in the prevalence of ciprofloxacin resistance (4,6). Prior
fluoroquinolone administration is a risk factor for resistant
strain selection, as observed for infections caused by S.
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a patient who had received long-term ciprofloxacin thera-
py to treat persistent bronchiectasis with Pseudomonas
aeruginosa infection (14).
Bacterial resistance to quinolones occurs mainly by
alteration of their intracellular drug targets, the DNA
topoisomerase IV (ParC2ParE2) and DNA gyrase
(GyrA2GyrB2) enzymes. The pneumococcal parC and
parE genes are homologous to gyrA and gyrB, respective-
ly (15,16). Genetic and biochemical studies have shown
that fluoroquinolones target primarily topoisomerase IV
and secondarily DNA gyrase in S. pneumoniae (16–19).
Resistance mutations are localized in the quinolone resist-
ance-determining regions (QRDRs) of ParC, ParE, and
GyrA. Low-level ciprofloxacin-resistant strains had muta-
tions altering the QRDR of one of the two subunits of
topoisomerase IV: S79 or D83 of ParC (16,17,20) or D435
of ParE (21). High-level ciprofloxacin-resistant strains had
changes affecting both QRDRs of ParC and GyrA (S81,
E85) (16,17) or ParE and GyrA (21). Genetic transforma-
tion experiments showed that single parC mutations con-
fer low-level ciprofloxacin resistance, and that once the
cells have acquired this phenotype, transforming to a high-
er level of resistance was possible by using DNA contain-
ing the gyrA QRDR from the high-level ciprofloxacin-
resistant strains (16,17). The description of recombinant
strains with a mosaic structure in their DNAtopoisomerase
genes (22–24) has established that fluoroquinolone resist-
ance in S. pneumoniae can be acquired by horizontal gene
transfer as well as by point mutation. VGS, which share
the same mechanisms of resistance (13), are donors in the
horizontal transfer to pneumococci (25) and act as a reser-
voir of fluoroquinolone resistance. To investigate the epi-
demiology of fluoroquinolone-resistant pneumococci,
ascertain the possible dissemination of international
clones, and determine the incidence of resistant strains
originated by interspecific horizontal transfer, we charac-
terized all ciprofloxacin-resistant S. pneumoniae strains
sent to Spanish Reference Laboratory during 2002.
Materials and Methods
Bacterial Strains, Serotyping, and Susceptibility Tests
We studied 2,882 S. pneumoniae strains submitted from
78 hospitals nationwide to the Spanish Reference
Laboratory during 2002. Of the submitted strains, 1,904
(66.1%) were isolated from adults and 978 (39.1%) from
children. The origin of isolates was as follows: 1,453
(50.4%) from blood or other sterile sites, 691 (24.0%)
from respiratory tract, 231 (8.0%) from eye swabs, 205
(7.1%) from ear swabs, and 302 (10.5%) from other sites.
Strains were confirmed as S. pneumoniae by standard
methods, and serotypes were determined by a quellung
reaction. Susceptibility tests, performed initially by the
agar-dilution method, selected 85 strains (one isolate per
patient) with ciprofloxacin MIC ≥ 4 µg/mL. The suscepti-
bility of these 85 strains was repeated twice by microdilu-
tion (Sensititre commercial plates) according to the
National Committee for Clinical Laboratory Standards
(NCCLS) methods (26). S. pneumoniae ATCC 49619 and
strain R6 were used for quality control. Fluoroquinolone
efflux was determined (27). 
Genetic Transformation 
S. pneumoniae strain R6 was grown in a casein
hydrolysate-based medium (AGCH) with 0.2% sucrose
and used as recipient in transformation experiments (20).
Cultures containing 4 x 106 CFU/mL were treated with
DNA at 0.15 µg/mL for 40 min at 30°C, then at 37°C for
90 min before plating on media plates containing 2.5
µg/mL of ciprofloxacin. Colonies were counted after 24 h
growth at 37°C in a 5% CO2 atmosphere in AGCH medi-
um with 1% agar. 
Southern Blot Analysis 
Probes for parC and  parE were amplified by poly-
merase chain reaction (PCR) of the R6 strain with oligonu-
cleotides parCUP and parCDOWN, parEUP and
parEDOWN, respectively (25). The ant probe was
obtained by amplifying strain 3870 DNA (22) with
oligonucleotides antUP and antDOWN (25). All probes
were labeled with the Phototope-Star Detection Kit (New
England Biolabs, Beverly, MA). Southern blot and
hybridization followed the manufacturer’s instructions.
Pulsed-field Gel Electrophoresis (PFGE)
Genomic DNAembedded in agarose plugs was restrict-
ed with SmaI, and fragments were separated by PFGE in a
CHEF-DRIII apparatus (Bio-Rad, Hercules, CA) (28).
PFGE patterns were compared to 14 representative inter-
national pneumococcal clones of the Pneumococcal
Molecular Epidemiology Network (28). Strains with pat-
terns varying by three or fewer bands were considered to
represent the same PFGE type (29). 
PCR Amplifications and DNA Sequence Determination 
Oligonucleotides gyrA44 and gyrA170 (13) were used
to amplify and sequence the gyrA QRDRs from chromoso-
mal DNA. Amplifications were performed with 0.5 U of
Thermus thermophilus thermostable DNA polymerase
(Biotools, Madrid, Spain), 0.1 µg of chromosomal DNA, 1
µmol/L (each) of the synthetic oligonucleotide primers,
and 0.2 mmol/L of each deoxynucleoside triphosphate
(dNTP) in the buffer recommended by the manufacturers.
Amplification was achieved with an initial cycle of 1 min
denaturation at 94°C; 25 cycles of 30 s at 94°C, 45 s at
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final 3-min 72°C extension step, followed by slow cooling
to 4°C. Fragments including ParE residues 398–647, the
intergenic  parE–parC region, and ParC residues 1–152
were amplified from genomic DNA with oligonucleotides
parE398 (13) and parC152 (16) in PCR reactions per-
formed as previously described, except that 30 cycles of
amplification with an extension step of 3 min were
applied. All strains, except three, CipR-73, CipR-74, and
CipR-75, which yielded fragments of 2.4, 3.0, and 2.9 kb,
respectively, yielded 1.6-kb fragments. Those PCR frag-
ments that contained both parE and parC QRDRs were
purified by using MicroSpin S400 HR columns
(Amersham Pharmacia Biotech, Pistcatway, NJ) and
sequenced on both strands with oligonucleotides parE398,
parE483 (13), parC50, and parC152 (16) with an Applied
Biosystems Prism 377 DNA sequencer, according to pro-
tocols provided by the manufacturer.
Statistical Analysis
The Fisher exact test (χ2 test) was used when appropri-
ate. Comparisons were considered significant at p < 0.05.
Results 
Among 2,882 strains, 75 (2.6%) had ciprofloxacin MIC
≥4 µg/mL by microdilution and were considered cipro-
floxacin-resistant. Ten strains with initial ciprofloxacin
MIC 4 µg/mLby agar-dilution showed MIC 1–2 µg/mLby
microdilution. Among the 75 ciprofloxacin-resistant
strains, 67% were isolated from sputum, whereas 19%
were from blood, 13% from lower respiratory tract sam-
ples, and 1.3% from pus. Although ciprofloxacin-resistant
strains belonged to 17 different serotypes, 6 serotypes
accounted for 55 (73.3%) of the strains: 14 (14 strains),
23F (11 strains), 19F (11 strains), 6B (8 strains),
3 (6 strains), and 15A (5 strains). These serotypes were
also the most frequent among the 2,807 ciprofloxacin-sus-
ceptible strains. No ciprofloxacin-resistance was found
among isolates from pediatric patients <15 years, whereas
the prevalence of resistance was 75 (3.9%) of 1,904 iso-
lates from adult patients (>15 years), and 53 (7.2%) of 738
isolates from patients ≥65 years (p < 0.001). The frequen-
cies of ciprofloxacin resistance were higher among nonin-
vasive pneumococci than among invasive strains (61
[4.3%] of 1,429 vs. 14 [1.0%] of 1,453, p < 0.001). 
An association between penicillin and ciprofloxacin
resistance was observed, with ciprofloxacin-resistant
strains distributed as follows: 17 (1.0%) of 1,658 penicillin-
susceptible, 39 (4.1%) of 961 intermediate-resistant, and 19
(7.2%) of 263 resistant isolates (p < 0.001). Ciprofloxacin-
resistant pneumococci were also more represented among
macrolide-resistant isolates: 22 (1.2%) ciprofloxacin-resist-
ant strains among 1,833 erythromycin-susceptible and 53
(5.1%) ciprofloxacin-resistant strains among 1,049 erythro-
mycin-resistant (p < 0.001). Antimicrobial-drug resistance
among the 2,807 ciprofloxacin-susceptible pneumococci
was lower than those of ciprofloxacin-resistant strains
(penicillin 41.4% vs. 73.3%, erythromycin 35.5% vs.
70.7%, tetracycline 33.6% vs. 69.3%, and chloramphenicol
15.4% vs. 44.0%, p < 0.001). Fifty-five (73.3%) of
ciprofloxacin-resistant strains showed multidrug resistance
(resistant to more than three chemically unrelated drugs),
among them, 26 strains were resistant to six antimicrobial
agents (penicillin, tetracycline, chloramphenicol, erythro-
mycin, clindamycin, and co-trimoxazole).
Fourteen (18.7%) ciprofloxacin-resistant (MIC
4–8  µg/mL) strains were classified as low-level
ciprofloxacin-resistant, and 61 (81.3%) strains were classi-
fied as high-level ciprofloxacin-resistant (MIC 16–128
µg/mL). The comparative in vitro activity of five fluoro-
quinolones (MIC90) against the ciprofloxacin-resistant
strains was the following: gemifloxacin (0.5 µg/mL)
> moxifloxacin  (4 µg/mL) > gatifloxacin (8 µg/mL)
> levofloxacin (32 µg/mL) > ciprofloxacin (64 µg/mL)
(Table 1). Gemifloxacin was the most active fluoro-
quinolone tested by using the NCCLS breakpoint (26),
49.3% of ciprofloxacin-resistant strains were nonsuscepti-
ble to this antimicrobial drug. Among the 14 low-level
ciprofloxacin-resistant isolates, 12 were susceptible to lev-
ofloxacin, 13 to gatifloxacin, and all were susceptible to
moxifloxacin and gemifloxacin according to NCCLS crite-
ria (26). However, all but one of these low-level
ciprofloxacin-resistant strains had first-step parC mutations
that would favor the appearance of high-level resistant
strains. Among the 61 high-level ciprofloxacin-resistant
strains, all showed cross-resistance to levofloxacin and gat-
ifloxacin and all but one to moxifloxacin. Twenty four
(39.3%) of 61 high-level ciprofloxacin-resistant strains had
gemifloxacin MIC 0.12 µg/mL, which could be considered
susceptible according to NCCLS (26), although they
showed double mutations (parC or parE and gyrA). One of
75 ciprofloxacin-resistant strains, strain CipR-71, with
MIC 8 µg/mL, had an efflux mechanism as the single cause
of resistance (see below). 
The parC, parE, and gyrA QRDRs of 85 strains (75
ciprofloxacin-resistant strains and 10 strains with
ciprofloxacin MIC 1–2 µg/mL) were characterized. Most
resistant strains (70 of 75) showed low nucleotide
sequence variations (<1%), but five strains had high varia-
tions (>4%) in at least one of their QRDRs (Figure). These
strains would have a mosaic structure in those genes show-
ing such a QRDR sequence variation (25): two strains in
parC, one in parC + parE, and two in parC + parE + gyrA.
Mosaic  parC genes had the N91D change, and mosaic
gyrA genes had the S114G GyrA change (Figure) that is
also present in other ciprofloxacin-resistant S. pneumoniae
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ceptible and -resistant VGS (25), which indicates their
recombinational origin. As expected (25), strains with
mosaic parE + parC genes had also an ant-like gene in the
intergenic parE–parC region (Figure).
All low-level ciprofloxacin-resistant strains had muta-
tions producing amino acid changes in ParC, whereas 92%
of high-level resistant strains had double (ParC + GyrA or
ParE + GyrA) and 8% had triple mutations (two changes
in ParC + GyrA, ParC + ParE + GyrA, ParC + two changes
in GyrA). Classical mutations known to be involved in flu-
oroquinolone resistance were found in all but two resistant
strains with mosaic parC genes (Table 2): D78A (strain
CipR-71) and S79R (strain CipR-75). Genetic transforma-
tion experiments showed that the S79R change was
involved in ciprofloxacin resistance and that the D78A
change was not. CipR-71 and CipR-75 chromosomal DNA
transformed the susceptible R6 strain to resistance with
high efficiency (>1 x 104 transformants per microgram of
DNA). The analysis of two transformants of each experi-
ment showed that, while transformants obtained with
CipR-71 DNA(ParC D78A) did not carry parC mutations,
those obtained with CipR-75 (ParC S79R) carried the same
nucleotide changes in parC as the donor strain.
When PCR products carrying ParE residues 398–647,
the intergenic parE–parC region, and ParC residues 1–152
(including ParE and ParC QRDRs) were used as DNA
donors, only those obtained from strain CipR-75 were able
to transform R6 to ciprofloxacin resistance. The two trans-
formants selected carried the ParC S79R change, and one
of them also had the N91D change. These results showed
that the S79R change is involved in the resistance pheno-
type of strain CipR-75 and that the D78A change of strain
CipR-71 is not involved in resistance. Determining MIC to
ciprofloxacin, norfloxacin, ethidium bromide, and acri-
flavine in the presence or absence of reserpine showed
greater than fourfold MIC decreases in the presence of
reserpine, both in the CipR-71 strain and in the two trans-
formants obtained when chromosomal DNA was used as
donor, which indicates the existence of an efflux mecha-
nism (data not shown).
Although 36 different PFGE patterns were observed in
the 75 ciprofloxacin-resistant strains, 48 strains can be
grouped into nine PFGE patterns (Table 3): 11 strains
belonged to Spain23F-1 clone, 8 strains to Spain14-5 clone,
6 strains to Spain9V-3 clone, 5 strains to Spain6B-2 clone, 5
strains to Sweden15A-25 clone, 4 strains to clone C of
serotype 19F, 4 strains to clone D of serotype 19F, 3 strains
to clone A of serotype 3 related to multilocus sequence
type (MLST) 260 (30), and 2 strains to clone B of serotype
3 related to MLST 180 (30). Among 14 blood isolates, 12
different PFGE types were observed. Only three of these
strains (CipR-1, -2, and -15) shared an identical PFGE
(clone A of serotype 3), although they had different parE
polymorphisms and different resistance patterns (Table 2). 
One of the strains with a mosaic parC gene belonged to
the Spain6B-2 clone, and one strain with mosaic parC and
parE genes belonged to the Spain23F-1 clone. Capsular
switching was observed in three strains of serotype 14 with
the Spain9V-3 clone, one strain of serotype 19F with
Spain9V-3 clone, and two strains of serotype 19A with
Spain23F-1 clone. In general, strains that shared the same
PFGE pattern shared identical polymorphisms on their
DNA topoisomerase QRDRs with respect to the sequence
of the R6 strain (Table 3). For instance, all strains of the
Spain9V-3 clone had identical polymorphisms, the same
found in the ATCC 700671 strain representative of this
clone (14). All but one of the strains belonging to the
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and a change in codon G128: GGT instead of GGC), two
polymorphisms in ParE (I460V and a change in codon
I476: ATT instead of ATC), and a change in codon Y75 of
GyrA (TAT instead of TAC). Identical polymorphisms
were found in the ATCC 700669 strain representative of
the Spain23F-1 clone (data not shown); the only exception
was the Spain23F-1 strain CipR-73 that had parC and parE
mosaic genes (Table 3). Other exceptions were three
strains of the Spain14-5 clone (CipR-38, CipR-39, and
CipR-40) that had an additional GyrA polymorphism
(V88I), which were isolated from three patients temporal-
ly related in the same hospital, and two other strains, CipR-
1 of clone A of serotype 3 and CipR-57 of clone D of
serotype 19F that showed different polymorphisms in ParE
(Table 3). 
Discussion
The worldwide prevalence of fluoroquinolone resist-
ance in S. pneumoniae is low, although it varies over time,
geographic region, age group, and origin of isolates
(1,4,6,31). The overall incidence of ciprofloxacin-resistant
S. pneumoniae strains in this study was 2.6%, lower than
that reported in previous studies (3%–7%) (4,5) conduct-
ed in Spain in which noninvasive isolates were predomi-
nant. In agreement with those previous studies,
noninvasive isolates in this study displayed ciprofloxacin
resistance as high as 4.3%. A higher prevalence (7.2%)
was seen in patients >65 years, which also agreed with
previous reports (4,6), and which possibly reflects
increased fluoroquinolone use in this group of patients.
The prevalence of ciprofloxacin resistance seen in this
study (2.6%) is similar to the 2.5% found among unselect-
ed isolates of Bellvitge Hospital (Barcelona) in 2002 (J.
Liñares, pers. comm.), but it is lower than the 6.3% found
in Donostia Hospital (San Sebastian) (E. Pérez-Trallero,
pers. comm.).
A significant relation between resistance to penicillin
or macrolides and resistance to ciprofloxacin was
observed (Table 1), in agreement with previous reports
(4,6). Penicillin- and multidrug-resistant pneumococci
have been common in Spain since the 1980s; these strains
primarily belong to serogroup 19 and to four multiresistant
epidemic clones: Spain23F-1, Spain6B-2, Spain9V-3, and
Spain14-5 (30,32,33). The emergence of fluoroquinolone
resistance among strains of these clones has been
described, (33–36) and in our study, resistance occurred
mainly among those four widely disseminated clones
(Table 3). Since neither temporal nor geographic relation-
ships were found among most patients infected by these
four clones, this finding could reflect the high prevalence
of these clones in the Spanish population, as suggested
previously (36), rather than the spreading of resistant
clones. Exceptions were five strains of the Spain14-5 clone
that could be grouped in two temporal clusters. One clus-
ter accounted for two strains (CipR-66 and -67) collected
in the same laboratory, with identical polymorphisms and
triple mutations in QRDRs. The second cluster accounted
for three identical strains of the Spain14-5 clone (CipR-38,
-39 and -40), which were recovered from three patients at
a laboratory from San Sebastian in a 29-day period. These
strains had an additional GyrA polymorphism (V88I) not
present in other Spain14-5 clone strains and may represent
a variant of this clone (33). Nevertheless, the epidemio-
logic features of these international clones (2,37,38) sug-
gest that dissemination of ciprofloxacin resistance through
these isolates is a plausible scenario and may predict a
rapid increase of resistance in S. pneumoniae in countries
with an increasing use of fluoroquinolones. Also plausible
is that recombinant ciprofloxacin-resistant isolates with
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Figure. Genetic organization of the parE–parC region of
Streptococcus pneumoniae mosaic strains and nucleotide
sequence variations in the ParC, ParE, and GyrA quinolone resist-
ance-determining regions. A) Structure as deduced from Southern
blot experiments and nucleotide sequence analyses. E, EcoRV; N,
NcoI. The parE and parC genes with a mosaic structure are shown
with darker gray arrows. B) Nucleotides present at each polymor-
phic site are shown for strain R6, but only sites that differ are
shown for the other strains. Amino acid changes involved in fluo-
roquinolone resistance are shown in boldface and underlined.
Codon numbers are indicated in vertical format above the
sequences. Positions 1, 2, and 3 in the fourth row refer to the first,
second, and third nucleotides in the codon. mosaic DNA topoisomerase genes belonging to the
Spain23F-1 and Spain6B-2 international clones (Table 3)
have disseminated and that these isolates have acquired
resistance mutations by horizontal transfer from VGS.
Although a low prevalence (5 [6.7%] of 75) of S. pneumo-
niae strains with mosaic parC  genes among the
ciprofloxacin-resistant strains was observed, the existence
of these kind of strains (Figure) is an indication that
recombination has occurred between resistant VGS and S.
pneumoniae, including the prevalent pneumococcal
clones. In addition, five resistant strains of the Sweden15A-
25 clone, another multiresistant clone previously reported
as susceptible (28), were found (Table 3). 
Although newer fluoroquinolones have enhanced in
vitro activity against S. pneumoniae and are less likely to
select for resistant isolates, their use to treat respiratory
tract infections merits special attention. More than 20
reports of levofloxacin treatment failure have been concur-
rent with the development of resistance during or after ther-
apy. In some cases, strains susceptible to levofloxacin but
with a first-step parC mutation, as a consequence of previ-
ous quinolone use, were present before therapy was initiat-
ed. Identifying these strains will help avoid therapeutic
failures. Since fluoroquinolone resistance is more frequent
in the elderly with chronic respiratory diseases who have
had long-term quinolone therapy (4,6,10–12,14), recent use
of these drugs should contraindicate further fluoro-
quinolone treatment. 
The use of NCCLS susceptibility breakpoints for newer
fluoroquinolones underestimates a high proportion of low-
level ciprofloxacin-resistant strains with first-step muta-
tions whose detection should be improved by decreasing
those breakpoints as previously suggested (11,39). In the
present study, which followed NCCLS criteria (26), 12
(85%) of 14 low-level ciprofloxacin-resistant strains with
a single parC mutation were susceptible to levofloxacin
(MIC 1–2 µg/mL). These data agree with those of other
authors who found parC mutations in 59% of the strains
with levofloxacin MIC 2 µg/mL (39). Using a
ciprofloxacin resistance breakpoint MIC ≥4 µg/mL, as was
used by Chen et al. (6), would improve detection of these
mutant strains. In fact, in our study, no strains with first-
step mutations and ciprofloxacin MIC 2 µg/mL were
detected, although other authors have found these muta-
tions in up to 29% of this type of strain (39). Although
gemifloxacin was the most active quinolone studied, and
39.3% of high-level ciprofloxacin resistance with double
mutations were gemifloxacin-susceptible with the NCCLS
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treated with any quinolone. To avoid treatment failures,
using microbiologic breakpoints for quinolone susceptibil-
ity would be more prudent than using clinical breakpoints.
If fluoroquinolones are widely and indiscriminately used,
resistance to fluoroquinolones in S. pneumoniae may
become a problem in the near future.
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A
ll my life my father refused to talk about
his boyhood in Norway. "No," he'd say when
I cajoled him for details. "I'm an American now." 
The only thing he'd ever talk about was how he'd
ended up in Minneapolis at Augsburg Seminary, 
the story of his "close call," as he referred to it. 
He was the only one of his three brothers and sister 
who emigrated. "He broke our mother's heart," my aunt
told me when I visited her in Norway many years later. 
She gave me the picture she'd taken the day he left, the
day after Christmas, 1920. He's impossibly young, already
wearing his life-long uniform - black suit, vest, white shirt, tie, 
ready to go off to America, even if his mother's 
heart is breaking, because he had to fulfill a promise
he made when he got the Spanish Flu, summer of 1918. 
"Twenty two million people died," he was fond of telling me, 
"twice as many as died in World War I, but I didn't die. 
When I was choking and close to death, my mother
called the village doctor who performed a tracheotomy
right on our kitchen table and I promised then I'd serve 
God forever if He wouldn't let me die. It was a close call." 
Close call, I say, echoing my father, now dead these 20 years. 
How close he came to being one of the 22 million, how he
almost didn't make it to America, almost didn't spend a
summer in Duluth, preaching at the Norwegian Seaman's
Mission, almost didn't meet my mother whose youth group
was serving coffee and cake after the service, almost didn't
marry her, almost didn't make love with her that warm June
evening of 1927, the night I was conceived, in the white frame
parsonage in Bagley, Minnesota. Close call. Close call.
Phebe Hanson (b. 1928)
From Why Still Dance, Nodin Press, 2003.
Reprinted with author's permission.
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